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Abstract
Background: Adequate vascularization is crucial for supplying nutrition and discharging metabolic waste in freshly
transplanted tissue-engineered constructs. Obtaining the appropriate building blocks for vascular tissue engineering
(i.e. endothelial and mural cells) is a challenging task for tissue neovascularization. Hence, we investigated whether
stem cells from human exfoliated deciduous teeth (SHED) could be induced to differentiate into functional vascular
smooth muscle cells (vSMCs).
Methods: We utilized two cytokines of the TGF-β family, transforming growth factor beta 1 (TGF-β1) and bone
morphogenetic protein 4 (BMP4), to induce SHED differentiation into SMCs. Quantitative real-time polymerase chain
reaction (RT-qPCR) was used to assess mRNA expression, and protein expression was analyzed using flow cytometry,
western blot and immunostaining. Additionally, to examine whether these SHED-derived SMCs possess the
same function as primary SMCs, in vitro Matrigel angiogenesis assay, fibrin gel bead assay, and functional
contraction study were used here.
Results: By analyzing the expression of specific markers of SMCs (α-SMA, SM22α, Calponin, and SM-MHC), we
confirmed that TGF-β1, and not BMP4, could induce SHED differentiation into SMCs. The differentiation efficiency was
relatively high (α-SMA+ 86.1%, SM22α+ 93.9%, Calponin+ 56.8%, and SM-MHC+ 88.2%) as assessed by flow cytometry.
In vitro Matrigel angiogenesis assay showed that the vascular structures generated by SHED-derived SMCs and human
umbilical vein endothelial cells (HUVECs) were comparable to primary SMCs and HUVECs in terms of vessel stability.
Fibrin gel bead assay showed that SHED-derived SMCs had a stronger capacity for promoting vessel formation
compared with primary SMCs. Further analyses of protein expression in fibrin gel showed that cultures containing
SHED-derived SMCs exhibited higher expression levels of Fibronectin than the primary SMCs group. Additionally,
it was also confirmed that SHED-derived SMCs exhibited functional contractility. When SB-431542, a specific
inhibitor of ALK5 was administered, TGF-β1 stimulation could not induce SHED into SMCs, indicating that the
differentiation of SHED into SMCs is somehow related to the TGF-β1-ALK5 signaling pathway.
Conclusions: SHED could be successfully induced into functional SMCs for vascular tissue engineering, and this
course could be regulated through the ALK5 signaling pathway. Hence, SHED appear to be a promising
candidate cell type for vascular tissue engineering.
Keywords: Tissue engineering, Angiogenesis, Stemness, Dental pulp stem cells, Smooth muscle cells
* Correspondence: zhangcf@hku.hk
1Comprehensive Dental Care, Endodontics, Faculty of Dentistry, The
University of Hong Kong, Pokfulam, Hong Kong, China
2HKU Shenzhen Institute of Research and Innovation, Hong Kong, China
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Xu et al. Stem Cell Research & Therapy  (2017) 8:10 
DOI 10.1186/s13287-016-0459-0
Background
Formation of blood vessels involves endothelial cells
lining the interior surface of the tubule wall, and perivas-
cular cells (vSMCs and pericytes) covering the exterior
of the vascular tube. Through direct interaction with
endothelial cells, perivascular cells play key roles as
guiders that facilitate sprouting of endothelial cells dur-
ing generation of new capillaries from immature blood
vessels [1], as well as in regulating both the stability and
contractile function of mature blood vessels [2]. There-
fore, generating functional perivascular cells is crucial
for vascular tissue engineering.
Most studies on vascular tissue engineering utilize com-
mercially available primary cells, such as human umbilical
vein endothelial cells (HUVECs), human umbilical artery
endothelial cells (HUAECs), vascular smooth muscle cells
(vSMCs), and pericytes (PCs) [3, 4]. Nevertheless, the
scarce availability of human tissue sources for primary cell
isolation, limited proliferative capacity, slow expansion
rate, and variability of tissue-specific phenotype would
hinder the clinical translation of mature ECs and vSMCs
[4]. Therefore, inducing human embryonic, induced
pluripotent, or adult stem cells, and endothelial pro-
genitor cells to generate ECs and vSMCs have been
explored [5, 6]. However, tumorigenicity, immuno-
compatibility and lack of precise control of differenti-
ation are challenges that need to be addressed.
Dental pulp stem cells can be readily harvested from
exfoliated deciduous or wisdom teeth, without imposing
additional discomfort or injury on patient donors. Not-
ably, stem cells from human exfoliated deciduous tooth
(SHED) exhibit faster and more extensive proliferative
capacity than bone marrow-derived mesenchymal stem
cells (BMMSCs) [7], and can differentiate into functional
endothelial-like cells [8, 9]. Currently within the scien-
tific literature, there is a lack of data on derivation of
vSMCs from SHED, and the utilization of these cells to
generate functional blood vessels.
Transforming growth factor beta 1 (TGF-β1) proteins
are the most potent soluble growth factors commonly uti-
lized for inducing stem/progenitor cell differentiation into
SMCs. The TGF-/Smad signaling pathway is critical for
differentiation of multipotent mesenchymal progenitors
into SMCs [10]. TGF-β stimulation and Notch activation
have been reported to induce differentiation of mesenchy-
mal stem cells (MSCs) and human embryonic stem cells
(hESCs) into SMCs [11]. Vo et al. [12] utilized TGF-β
combined with platelet-derived growth factor (PDGF-BB)
to induce differentiation of hESCs into smooth muscle
cells. Additionally, TGF-β1 alone or in combination with
other factors can also effectively induce adult stem cells
into the SMC lineage. For example, adipose-derived stem
cells exposed to a combination of TGF-β1 and bone
morphogenetic protein 4 (BMP4), could differentiate into
SMCs [13]. TGF-β1 combined with ascorbic acid was
demonstrated to induce bone marrow-derived mesenchy-
mal stem cells into SMCs [14].
Hence, the objective of this study was to differentiate
SHED into SMCs by TGF-β1 alone or in combination
with BMP4, and to investigate the functionality of the
derived SMCs.
Methods
Cell culture
SHED were purchased from ALLCELLS (Alameda, CA,
USA), and were evaluated for their “stemness” before in-
duction. The expression of stem cell associated phenotypic
markers, CD73, CD90, CD105, and CD45, were analyzed
by flow cytometry (Additional file 1: Figure S1). In
addition, the multiple differentiation capacity of SHED
was confirmed using adipogenic, osteogenic, and neuro-
genic induction media (Additional file 2: Figure S2).
HUVECs and primary SMCs were purchased from
ScienCell (Carlsbad, CA, USA) and were cultured in
fully supplemented endothelial growth medium (EGM-2,
Lonza, Walkersville, MD, USA) and smooth muscle cell
medium (SMCM, ScienCell) respectively.
In vitro differentiation and expansion of SHED-derived
SMCs
SHED were plated at a density of 3 × 103 cells/cm2 and
cultured in α-MEM supplemented with 10% (v/v) FBS
until 70% confluency. Differentiation was induced in α-
MEM with 5% (v/v) FBS supplemented with TGF-β1
(2.5, 5, 10, 20, 30 ng/ml) (Peprotech, Rocky Hill, NJ,
USA) and/or BMP4 (5, 10, 30 ng/ml) (Peprotech), with
medium being refreshed every other day. On day 7, the
induced SHED were expanded in α-MEM with 5% (v/v)
FBS supplemented with 1 ng/ml TGF-β1, to obtain
SHED-derived SMCs at passage 1 to 2.
RT-qPCR
Real-time quantitative PCR was performed according to
previously described protocol [15]. The utilized primer se-
quences were as follows: GAPDH, 5′-TGCACCACCA
ACTGCTTAGC-3′, 5′-GGCATGGACTGTGGTCATGA
G-3′; α-SMA, 5′-CCGACCGAATGCAGAAGGA-3′, 5′-A
CAGAGTATTTGCGCTCCGAA-3′; SM22α, 5′-AGTGC
AGTCCAAAATCGAGAAG-3′, 5′-CTTGCTCAGAATC
ACGCCAT-3′; Calponin,5′-GTCAACCCAAAATTGGCA
CCA-3′, 5′-ACCTTGTTTCCTTTCGTCTTCG-3′.
Western blot
Western blot analyses of protein expression were also
performed as previously described [15]. The following
primary antibodies were used: mouse monoclonal anti-
β-actin monoclonal antibody (sc-47778; Santa Cruz
Technology, Dallas, TX, USA); rabbit polyclonal anti-
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SM22 alpha antibody (ab14106; Abcam, Cambridge,
MA, USA); rabbit monoclonal anti-Calponin antibody
(ab46794; Abcam); mouse monoclonal anti-Fibronectin
antibody (MA5-11981; Thermo Fisher Scientific, Waltham,
MA, USA); and Smad2/3 antibody kit (#12747; Cell Signal-
ing Technology, Danvers, MA, USA).
Immunocytochemistry
After differentiation, SHED-derived SMCs were fixed
with 4% (w/v) cold PFA for 15 minutes and washed with
PBS. The cells were then permeabilized using 0.1% (v/v)
Triton-X100 for 10 minutes. Primary antibodies against
α-SMA (A2547; Sigma-Aldrich, St. Louis, MO, USA),
SM22 alpha (ab14106; Abcam), smooth muscle Myosin
heavy chain 11 (ab683; Abcam) and Calponin (ab46794;
Abcam) were utilized for immunocytochemical staining.
Goat anti-mouse immunoglobulin G (IgG) H&L (Alexa
Fluor® 488) pre-adsorbed (ab150117; Abcam) and goat
anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077;
Abcam) were utilized as secondary antibodies. Primary
SHED and SMCs were used as negative and positive
controls. The images were viewed and captured under
fluorescence microscopy.
Flow cytometry analysis
BD Cytofix/Cytoperm™ Fixation/Permeabilization Kit
(554714; BD Biosciences, San Jose, CA, USA) was used
in flow cytometry to detect the expression of the various
aforementioned smooth muscle cell markers by SHED-
derived SMCs. Cell dissociation solution (C5914; Sigma-
Aldrich) was used to disperse the SHED-derived SMCs.
After fixation and permeabilization, cells were incubated
for 2 hours with primary antibodies against α-SMA
(ab124964; Abcam), SM22 alpha (ab14106; Abcam),
smooth muscle Myosin heavy chain 11 (ab683; Abcam),
Calponin (ab46794; Abcam), and then washed with PBS.
This was followed by incubation with the appropriate
secondary antibodies: goat anti-mouse IgG H&L (Alexa
Fluor® 488) pre-adsorbed (ab150117; Abcam) and goat
anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077;
Abcam). In this study, mouse IgG1, kappa monoclonal
(ab170190; Abcam) and rabbit IgG, monoclonal
[EPR25A] (ab172730; Abcam) were utilized as the iso-
type control. Flow cytometry data was analyzed with
FACSVerse software (BD Biosciences).
In vitro Matrigel angiogenesis assay
To investigate whether SHED-derived SMCs could pro-
mote the stability of blood vessel structures, the in vitro
Matrigel angiogenesis assay was performed according to
established protocols [16], where the time course of vas-
cular structure was evaluated to assess its stability.
Briefly, HUVECs were seeded at 36,000 cells per well of
48-well plates that had been pre-coated with Growth
Factor-Reduced Matrigel (354230, BD Biosciences). After
6 hours incubation at 37 °C and 5% CO2, different
groups of cells (group 1: SHED-derived SMCs; group 2:
SHED; group 3: primary SMCs) were added to Matrigel
surface at a density of 7200 cells/well. Images were cap-
tured over 48 hours. For some applications, CellTracker®
fluorescent probes (Life Technologies, Carlsbad, CA,
USA) were used to label different cell types to distin-
guish them within vessel-like structures. HUVECs were
stained with red fluorescence (Cell Tracker® Red
CMTPX Dye, Life Technologies), while SHED-derived
SMCs/primary SMCs were stained with green fluores-
cence (Cell Tracker® Green CMFDA Dye, Life Technolo-
gies). Images were captured under fluorescence
microscopy, and were analyzed using Image J software
(US National Institutes of Health, Bethesda, MD, USA).
Fibrin gel bead assay
Fibrin gel bead assay can be used to model the entire
process of angiogenesis [17], by seeding endothelial
cells on the surface of Cytodex microcarrier beads
followed by culture on the fibrin gel to form vessel
structures. Briefly, 2500 pre-sterilized Cytodex® 3
microcarrier beads (C3275, Sigma-Aldrich) were mixed
with 1 × 106 HUVECs (p3 to 5) in 1.5 ml of EGM-2
medium (Lonza) within a FACS tube. The FACS tube
was then placed within the incubator vertically with
slight agitation every 20 minutes for more than 4 hours.
Subsequently, 5 ml of fresh pre-warmed EGM-2
medium was added to the FACS tube, followed by pip-
etting to a T-25 flask for incubation at 37 °C and 5%
CO2 overnight. Aliquots of 1 × 10
4 cells (group 1:
SHED-derived SMCs; group 2: SHED; group 3: primary
SMCs) were mixed with 250 pre-coated beads in 500 μl
of 2 mg/ml fibrinogen solution per well of a 24-well
plate. The beads-fibrinogen solution was coagulated by
adding thrombin (T7513, Sigma-Aldrich) at a concen-
tration of 0.625 units/ml, and was then allowed to clot
for 5 minutes at room temperature, followed by another
25 minutes incubation at 37 °C and 5% CO2. A total of
350 μl of fresh pre-warmed EGM-2 medium was then
added to the surface of the clotted fibrin gel with
medium being refreshed every 2 days. After 10 days,
images were captured and analyzed using Image J
software.
Subsequently, proteins of each group were extracted
for further analysis. Briefly, gels were washed with cold
PBS, and 250 μl of RIPA lysis buffer was added to each
well, followed by transfer to a 1.5 ml Eppendorf tube.
The gels and RIPA mixtures were then homogenized
with two cycles of 30-second sonication and 20-second
vortexing. The lysates were then centrifuged for 10
minutes at 4 °C, and the supernatant was collected for
further analysis.
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Functional contraction study
The contractility assay was performed according to an
established protocol [18]. Briefly, cells were detached
using Trypsin, and the concentration was adjusted to
1.5 × 105cells/ml. Then 0.4 ml of cell suspension and 0.2
ml of 3 mg/ml collagen solution (R&D Systems Minne-
apolis, MN, USA) were mixed thoroughly in a 1.6 ml
Eppendorf tube (this volume is only for one well of a 24-
well plate). After adding an appropriate volume of 1 M
NaOH to the mixture of cells and collagen, 500 μl of the
mixture was immediately transferred to a well of a 24-
well plate. Gels were allowed to solidify for 20 minutes
at room temperature, and then transferred into a 37 °C
incubator with a humidified 5% CO2 atmosphere. The
extent of gel contraction was measured by calculating
the area of gel with the Image J software.
Statistical analysis
All numerical data were expressed as mean ± standard
deviation (SD). One-way ANOVA was utilized for statis-
tical analysis. The threshold of statistical significance
was set at p < 0.05.
Results
TGF-β1 can induce the differentiation of SHED into SMCs
As two distinct cytokines of the TGF-β family, TGF-β1
and BMP4 were arbitrarily selected to induce SMCs dif-
ferentiation. To evaluate whether TGF-β1 and BMP4
could induce SHED to functional SMCs, various combi-
nations and concentrations of TGF-β1 and BMP4 were
investigated. As shown in Fig. 1a, after 7 days induction,
TGF-β1 upregulated the mRNA expression levels of
SMCs specific markers (α-SMA, SM22α and Calponin),
but there was no significant differences between the
different concentrations of 10 ng/ml, 20 ng/ml and 30
ng/ml. BMP4 alone exerted negligible effects on the dif-
ferentiation of SHED into SMCs. However when it was
used in combination with TGF-β1, the effect of TGF-β1
was weakened (Fig. 1b, c). Hence, only the dose of 10
ng/ml TGF-β1 was utilized in further studies.
To assess the time-course effect of 10 ng/ml TGF-β1
on SMCs differentiation, we analyzed the mRNA (Fig. 2a)
and protein (Fig. 2b) expression levels of SMCs specific
markers on day 3, 5, and 7, passage1 and 2.The results
showed that the expression of SMCs specific markers at
the transcriptional level reached the highest level on day
5, with a slight decline on day 7. Although the expres-
sion levels of SMCs specific markers declined signifi-
cantly by passage 1 and 2, these were still higher than
undifferentiated SHED (except SM22α). As shown in
Fig. 2c, SB-431542, a specific inhibitor of ALK5, could
suppress TGF-β1-mediated SMC differentiation. To
evaluate the signaling mechanisms involved in SHED-
SMCs differentiation, we treated cells with TGF-β1 and
evaluated the phosphorylation of Smad2/3. The results
showed that Smad2/3 became phosphorylated within 30
minutes of exposure to TGF-β1, and that SB-431542
inhibited this phosphorylation (Fig. 2d).
To evaluate the efficiency of SMCs differentiation, the
percentages of α-SMA, SM22α, Calponin, and smooth
Fig. 1 SMC-specific marker gene expression profile of SHED-derived SMCs induced with different concentrations and combinations of TGF-β1
and BMP4. Expression levels of SMC-specific marker genes relative to GAPDH with (a) different doses of TGF-β1 induction. There was significant
upregulation of α-SMA and Calponin 1 gene expression levels as the TGF-β1 concentration is increased from 2.5 ng/ml to 10 ng/ml (p < 0.05).
There were however no significant differences between the 10 ng/ml, 20 ng/ml and 30 ng/ml TGF-β1 treatment groups (p > 0.05). SM22α gene
expression was a little different, by which 5 ng/ml TGF-β1 had a same effect with 10 ng/ml, 20 ng/ml and 30 ng/ml. b Different doses of BMP4
induction and with different combinations of TGF-β (10 ng/ml) and BMP4 (5, 10, 30 ng/ml). There were no significant differences amongst the
different doses of BMP4 (p > 0.05), and also no significant differences amongst the different combinations of TGF-β and BMP4 (p > 0.05). c 10
ng/ml TGF-β1, 10 ng/ml BMP4 and the combination of 10 ng/ml TGF-β1 with BMP4. The effect of TGF-β1 was weakened when combined with
BMP4 (p < 0.05). * ^ Φ: p < 0.05. B means BMP4; TB means TGF-β and BMP4. All experiments were performed three times (N = 3). BMP4 bone
morphogenetic protein 4, TGF-β1 transforming growth factor beta 1, α-SMA alpha-smooth muscle actin
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muscle-myosin heavy chain (SM-MHC) positive cells
were quantified by flow cytometry analysis on day 7. As
shown in Fig. 2e, high proportions of the cell popula-
tion were positively expressing the various SMCs
markers on day 7 (α-SMA+ 86.1%, SM22α+ 93.9%,
Calponin+ 56.8%, and SM-MHC+ 88.2% respectively).
Additionally, immunocytochemistry was also performed
on day 7 (Fig. 2f ).
Fig. 2 Characterization of SHED-derived SMCs. a Expression levels of SMC-specific marker gene expression relative to GAPDH at different induction
time points. The expression levels of all SMC-specific marker genes peaked on day 5 (p < 0.05, compared with other time points). At passage 2, the
gene expression levels of α-SMA and Calponin 1 declined but were still significantly higher than the control group (p < 0.05); while the gene expression
level of SM22α declined to the same level as the control group (p > 0.05). * ^ Φ: p < 0.05 compared to all other time points. b The protein expression
levels of SM22α and Calponin 1 were analyzed by western blot utilizing β-actin as the internal marker. Numbers depict the band density normalized
against untreated controls and β-actin. c SB-431542 suppressed TGF-β1-mediated SMC differentiation. * ^ Φ: p < 0.05 between TGF-β1 group
and SB-431542 + TGF-β1-treated group. d Smad2/3 became phosphorylated within 30 minutes of exposure to TGF-β1, and SB-431542 inhibited this
phosphorylation. Numbers depict the band density normalized against untreated controls and β-actin. e SHED-derived SMCs were also analyzed for
expression of SMC-specific markers (α-SMA, Calponin, SM22α and SM-MHC) with flow cytometry (α-SMA+ 86.1%, SM22α + 93.9%, Calponin + 56.8%, and
SM-MHC+ 88.2% respectively) (the isotype control in red) and (f) immunofluorescence staining (nuclei in blue). All experiments were performed three
times (N = 3). SM-MHC smooth muscle-myosin heavy chain, SHED stem cells from human exfoliated deciduous teeth, α-SMA alpha-smooth muscle actin
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SHED-derived SMCs exhibit similar functional properties
as primary SMCs
The results of the contractility assay revealed that SHED-
derived SMCs displayed similar contractile function as
primary SMCs (Fig. 3). The results of the Matrigel tube
formation assay showed that SHED-derived SMCs display
close localization with endothelial cells. As shown in
Fig. 4a, the co-culture of SHED-derived SMCs and
HUVECs resulted in the formation of three-dimensional
vessel structures that appear to recapitulate the interac-
tions of ECs with SMCs in vivo. Furthermore, the time
course of vascular structure formation by SHED-derived
SMCs and HUVECs was similar to that generated by
primary SMCs and HUVECs (Fig. 4b).
The three-dimensional fibrin gel bead assay demon-
strated the capacity of SHED-derived SMCs to promote
tube formation. Figure 5a provides a schematic represen-
tation of calculating tube formation from fibrin beads
[19]. The results showed that SHED-derived SMCs had
a stronger capacity than primary SMCs in promoting
tube formation (Fig. 5b, c).
To further investigate the mechanisms by which the
formation of vessels is regulated by perivascular cells,
the protein expression levels of Fibronectin were
assessed. The results showed that cultures containing
SHED-derived SMCs exhibited higher expression levels
of Fibronectin than the primary SMCs group (Fig. 5d).
Discussion
Primary human SMCs obtained from either autologous
or allogeneic sources are not an ideal candidate for
vascular tissue engineering due to their low replicative
capacity and scarce availability [20]. Human pluripotent
stem cells [5, 12], human induced pluripotent stem cells
[21], and bone marrow-derived mesenchymal stem cells
[22] have been demonstrated to possess the capacity to
generate functional SMCs, but there are still some obsta-
cles limiting their clinical applications, such as ethical
concerns pertaining to the cell sources [23], as well as
the risk of carcinogenesis after transplantation [24].
As a novel subpopulation of adult stem cells, stem
cells from human exfoliated deciduous teeth (SHED),
which are derived from a naturally occurring exfoliated
tissue, present a unique stem cell source for potential
clinical applications [25]. Besides their multi-potential
differentiation capacity to differentiate into the neural,
osteoblast, and adipocyte lineages [26, 27], SHED have
also been demonstrated recently to differentiate into
endothelial cells, which involves the MEK1/ERK signal-
ing pathway [8]. However, there is as yet no report of
SHED differentiating into SMCs. In this study, we dem-
onstrated that under the stimulatory effects of TGF-β1,
SHED could differentiate into functional SMCs. α-SMA
is the most widely recognized marker of SMCs [28], but
it is still necessary to combine this with other markers
to positively identify SMCs. These include SM22α,
Calponin, and particularly SM-MHC, which are believed
to be expressed only in contractile SMCs [29]. The re-
sults of this study showed that all these SMCs markers
could be detected (like Calponin) or enhanced (like α-
SMA) when SHED were stimulated with TGF-β1. Fur-
thermore, upon expanding the SHED-derived SMCs to
passage 1 and 2, there was observed to be stable expres-
sion of α-SMA, SM22α, Calponin, and SM-MHC at pas-
sage 1.
Besides exhibiting the typical phenotype of SMCs, ma-
ture vascular SMCs also need to display functional char-
acteristics, such as the ability to stabilize blood vessels,
promote vascular formation and display contractile func-
tion to regulate blood pressure [2]. During the course of
in vivo vascular formation, primary SMCs are recruited
to the vicinity of vessels formed by endothelial cells
Fig. 3 Collagen gel contraction assay. Gel surface areas were measured and further analyzed using the Image J software. *: p < 0.05, ^: p > 0.05.
HUVECs human umbilical vein endothelial cells, SHED stem cells from human exfoliated deciduous teeth
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Fig. 4 Vascular tube formation by SHED-derived SMCs and ECs on Matrigel. a Immunofluorescence image of vascular structure (EC in red; SHED-
derived SMCs in green). (b) Phase-contrast images (×10) of vascular structures from 4 hours to 24 hours after seeding ECs and SHED-derived SMCs
on Matrigel. HUVECs human umbilical vein endothelial cells, SHED stem cells from human exfoliated deciduous teeth, SMCs smooth muscle cells
Fig. 5 SHED-derived SMCs promote EC vessel formation. a Photomicrographs of EC-coated microbeads cultured in fibrin gels with SMC, SHED and
SHED-induced SMC on the gel surface. b The schematic representation of calculating tube formation from each bead: (i) the number of vessels which
sprout from the bead directly (in blue); (ii) the total number of individual vessel segments (including blue and yellow); and (iii) the total length of all the
vessel segments. c Quantification of the vessel structures in the fibrin gel bead assay in the presence of SMC, SHED and SHED-induced SMC.*: p < 0.05
versus SMCs group, ^: p < 0.05 between SHED and SHED-derived SMCs. d Western blot showing fibronectin expression within each experimental
group. All experiments were performed three times (N = 3). ECs endothelial cells, SHED stem cells from human exfoliated deciduous teeth, SMCs
smooth muscle cells
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through extracellular matrix (ECM) production and
cytokine interaction, and serve to stabilize the nascent
capillary during the early stages of vessel formation [30].
At later stages, these SMCs acquire a contractile func-
tion under the effects of different stimulatory cues [31].
To evaluate the ability of SHED-derived SMCs in sta-
bilizing and promoting engineered vascular networks,
two three-dimensional angiogenesis assays were per-
formed in this study. First, we examined the in vitro
formation of capillary-like structures by co-culture of
HUVECs and SHED-derived SMCs on Matrigel. Because
the in vitro Matrigel angiogenesis assay is rapid, reliable
and quantitative, it has been widely used to study the
regulatory mechanisms of angiogenesis [32]. The ob-
served long-term stability would thus indicate that
SHED-derived SMCs had similar capacity to generate
vascular-like structures as primary SMCs. Second, we
examined the capacity of perivascular cells to enhance
the process of vascularization in fibrin gel. The number
of vessels which sprout from the beads directly, the total
number of individual vessel segments and the total
length of all the vessel segments were three parameters
utilized in evaluating vascular structures in the fibrin gel
bead assay [20]. It is interesting that the capacity of
SHED-derived SMCs to enhance vascular formation was
better than primary SMCs. ECM proteins, particularly fi-
bronectin, have been widely reported as inductive factors
in regulating angiogenesis. An in vivo study showed that
fibronectin-binding integrin α5β1 can enhance angio-
genesis [33], and this result was further confirmed by
another study [34]. Therefore, we attempted to analyze
fibronectin expression. The results showed that higher
expression levels of fibronectin were detected in the
vessel structures composed of HUVECs and SHED-
derived SMCs, as compared to the HUVECs with pri-
mary SMCs group. These findings led us to propose a
hypothesis that stem cells with strong capacity for
producing ECM make them better at promoting
angiogenesis than SMCs.
Contractility is a key characteristic and distinguishing
property of mature SMCs, which enables blood vessels
to control appropriate blood pressure through alteration
of the luminal diameter by contraction and relaxation
[18]. An in vitro assay utilizing collagen gel for monitor-
ing the contraction of smooth muscle cells has been
widely accepted as a classical test model for assaying
contractility [18]. In this study, SHED-derived SMCs
were found to be capable of contracting when cultured
in collagen gel, thus exhibiting similar functional charac-
teristics as primary SMCs.
As a superfamily of growth factors and cytokines, the
TGF-β superfamily includes the various TGF-β isoforms,
Nodals, Activin, and BMPs, which play crucial roles in
diverse biological processes, such as cell differentiation
[35]. The initiation of TGF-β signaling is triggered
through the binding of TGF-β cytokines to their cognate
receptors (TGF-β RI and RII). Upon ligand binding, the
activated TGF-β RI recruits and phosphorylates Smad
proteins, i.e. Smad 2/3 for TGF-βs, Activin, Nodals, and
Smad 1/5/8 for BMPs [35]. Many studies [36, 37] have
reported that it is Smad 2/3 which play an important
role in SMCs differentiation. However, there are also
studies [13, 38] which have shown that BMP4 could me-
diate SMCs differentiation via the Smad 1/5/8 pathway.
Therefore in our study, we selected TGF- β1 and BMP4
as two representative growth factors of the TGF-β super-
family to induce SMCs differentiation. The results of this
study conclusively demonstrated that BMP4 alone
exerted negligible effects on the differentiation of SHED
into SMCs. Furthermore, the effects of TGF-β1 on
SHED-SMCs differentiation could be weakened when
combined with BMP4. We hypothesize that BMP4 might
compete with TGF-β1 for binding to TGF-β receptors
(TGF-β RI and RII) during the process of SHED-SMCs
differentiation. Although accumulated evidence shows
that BMPs play crucial roles in the regulation of stem
cell properties and lineage fate, their functions vary with
different stem cell types. While the differentiation of
SHED into SMCs could be mediated by TGF-β1, no sig-
nificant differences were observed between concentra-
tions of 10 ng/ml to 30 ng/ml TGF-β1. The results of
our analysis of the Smad signaling pathway showed that
upon interaction with TGF-β1, the TGF receptors re-
cruited and phosphorylated the downstream targets of
Smad 2 and 3. Besides this classical signaling pathway,
several other signaling pathways that affect SMC differ-
entiation under TGF-β1 stimulation have also been re-
ported, such as the p38 [39], AKT [40], and RhoA [41]
signaling pathways. In this study, we investigated the ef-
fects of SB-431542, a specific inhibitor of ALK5 [42], on
the differentiation of SHED into SMCs. In the presence
of SB-431542, SHED could not be induced into SMCs
under TGF-β1 stimulation, which thus confirmed the
crucial role of the TGF-β1-ALK5 signaling pathway in
modulating the differentiation of SHED into SMCs.
This finding could explain why BMP4 had negligible ef-
fects on the course of differentiation of SHED into
SMCs. Unlike TGF-β1, BMP4 functions through Alk2,
Alk3 and Alk6 that mediate phosphorylation of Smad1,
Smad5, or Smad8, which in turn modulate target gene
expression at the transcriptional level [43].
Conclusions
Our data confirmed that SHED possess the capacity to
differentiate into functional smooth muscle cells. Further
analysis of the results revealed that TGF-β1 regulate
SHED differentiation into smooth muscle via the ALK5
Xu et al. Stem Cell Research & Therapy  (2017) 8:10 Page 8 of 10
signaling pathway. Hence, SHED appear to be a promis-
ing candidate cell type for vascular tissue engineering.
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